As demonstrated by American Society of Plastic Surgeons statistics (2013), patients seeking nonsurgical facial rejuvenation are increasing. A variety of temporary and semipermanent soft-tissue fillers, such as hyaluronic acid, poly-L-lactic acid, and calcium hydroxylapatite, are readily available; however, they have not been proven effective in treating facial acne scarring. Patient tolerance for the inconvenience and repeat cost of short-term, temporary fillers is waning as newer generation fillers with longer durations are coming on the market. Permanent injectable fillers, such a Bellafill (Suneva Medical Inc., San Diego, Calif.), represent a desirable solution for patients who want a long-term result. With the recent Food and Drug Administration approval for the treatment of moderate-to-severe, atrophic, distensible facial acne scars on the cheek(s) in patients over the age of 21 years, Bellafill (polymethylmethacrylate collagen) represents an effective solution for the treatment of facial acne scarring of the face while maintaining an excellent safety profile.